Last reviewed · How we verify
Intrathecal triple chemotherapy
At a glance
| Generic name | Intrathecal triple chemotherapy |
|---|---|
| Sponsor | The Korean Society of Pediatric Hematology Oncology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (PHASE2)
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) (PHASE1)
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane (PHASE1)
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML (EARLY_PHASE1)
- A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol (PHASE3)
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood (PHASE1, PHASE2)
- CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: